AXL and nonpapillary renal cell carcinoma: Similarly, in patients with ovarian cancer or endometrial cancer, high AXL expression is associated with poor chemoresponse [58, 59] and patients with ccRCC who have high AXL expression shows lower objective response rate to PD-1 inhibition therapy [60].